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1 Introduction 
 
The East Midlands explicitly recognises that a number of key sectors make an important contribution 
to the regional economy in the drive to increase productivity and competitiveness and achieve the 
objectives of the Regional Economic Strategy (RES). Priority sectors require targeted intervention to 
improve significantly the contribution they can make in areas such as innovation, sector networks, 
supply chain development and skills. 
 
Healthcare and Bioscience has been highlighted as a key sector in the future economic development 
of the East Midlands region. Health was ranked as the 5th highest sector overall; accounting for 6.9% 
of regional GVA, 9.7% of regional employment, and having a forecasted employment growth of 
18.1% and output growth of 47.1%.  
 
This document sets out the delivery plans for the Healthcare and Bioscience sector over the period 
2007-12 in order to achieve the aims of the RES. It sets out key issues, market failures and 
interventions required in order for the Healthcare and Bioscience sector to overcome barriers to 
growth and realise its full potential. It is intended to highlight the main areas of focus and key players. 
The document is not an exhaustive list and recognises that there are other organisations active in the 
Healthcare and Bioscience sector, which could play a role in the future prosperity of the sector.  
 
The delivery plan pulls together several surveys and consultations that have taken place, over a 
number of years, with industry, Higher Education Institutes (HEIs) and other interested parties. This 
is however, only the start of this process and the strategy should be reviewed on a regular basis in 
order to ensure that the key issues and market failures remain valid and interventions are being 
delivered in the most appropriate manner in order to ensure the needs of the sector are met. For a 
list of key contributors to the strategy see supporting material. 
 
2 Role in the East Midlands Economy 
 
2.1.1 National Perspective 
 
The Healthcare and Bioscience sector can be broadly defined as comprising pharmaceuticals, 
medical technology (devices, diagnostic equipment, and assistive technologies), red biotechnology 
(i.e. biotechnology related to medical processes) and specialist supporting services (contract 
research, packaging, sterilisation, raw material manufacture, technical consultancy etc). All these are 
driven by the demand for improvements in health predominantly through the NHS, retail pharmacy or 
exports. The Healthcare and Bioscience sector in the UK (and most of the world) is growing, 
reflecting an ageing, active population with higher expectations for health and well being. 
 
Medical Device Market 
The global medical technology market in 2003 was valued at £125 billion and the UK has one of the 
largest medical device markets in the world, valued at £4.4 billion in 2006. The domestic market is 
the third largest in Europe behind Germany and France. The NHS is the principal purchaser of high 
cost devices, with total NHS expenditure in England estimated to increase to £76,144 million in 
2005/06. There are currently significant changes taking place in the way the NHS purchases with the 
development of regional procurement confederations covering entire Strategic Health Authorities 
(SHAs) and a move to greater emphasis on purchasing by Primary Care Trusts. 
 
The UK market for medical devices is expected to experience above average growth over the next 
five years. The government raised health expenditure by approximately 50% between 1997 and 2004 
and is committed to increasing Healthcare and Bioscience expenditure by at least 7% per annum 
until 2008. Post-2008; if the government adheres to the 2002 Wanless report, Healthcare and 
Bioscience expenditure will have to increase year on year by between 4% and 5% until at least 2012. 
According to Espicom the real annual growth over the next five years is estimated to be 12.3%, which 
would take the market to £8 billion by 2011. 
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Projected UK Medical Device Market, 2006-2011:  
Year Market size (£ millions) Per Capita (£) 
2006 4,416 73 
2007 4,951 82 
2008 5,559 92 
2009 6,248 103 
2010 7,031 115 
2011 7,922 129 
Source: Espicom estimates. 
Pharmaceutical Market 
The UK pharmaceutical industry is the fourth largest in the world, accounting for 12% of the world 
market. It is home to a number of the sector’s largest companies including; GlaxoSmithKline and 
AstraZeneca. Behind these, there are a large number of smaller companies specialising in R&D and 
biotechnologyy products. The UK is credited with the discovery and development of a quarter of the 
world's top 100 medicines, more than any country except the USA. The Association of the British 
Pharmaceutical Industry (ABPI) claims that a quarter of the entire research expenditure by the UK 
manufacturing sector is funded or carried out by the pharmaceutical sector. Research and 
development expenditure by the pharmaceutical industry in Britain amounts to more than £3 billion. 
Official figures placed total UK pharmaceutical output at £9.5 billion in 2004. Espicom predicts that 
the pharmaceutical market growth is estimated at 5.3% per annum in real terms until at least 2011. 
The current market size is estimated at £14.7 billion in 2006, increasing to £20.9 billion by 2011, 
equal to £341 per capita. 
Projected UK Pharmaceutical Market, 2006-2011:  
Year Market size (£ millions) Per Capita (£) 
2006 14,734 244 
2007 15,810 262 
2008 16,964 279 
2009 18,202 299 
2010 19,532 319 
2011 20,957 341 
Source: Espicom estimates. 
Biotechnology Market 
The United Kingdom (UK) biotechnology industry remains the second largest in the world, after the 
United States and is the largest within Europe by a considerable margin. The market’s year-on-year 
growth rates have accelerated in recent years, a trend expected to continue. The UK accounts for 
93% of all publicly quoted bioscience companies in Europe, with a combined market capitalisation of 
£5 billion and is one of the fastest growing industries in the UK, with employment expanding at over 
20% annually. 
 
The United Kingdom biotechnology market generated total revenues of £4.3 billion in 2005, 
representing a compound annual growth rate (CAGR) of 9.3% for the five-year period spanning 
2001-2005. The United Kingdom currently accounts for 37.8% of the European market revenues. In 
comparison, Germany and France, the next two largest markets, generated 21.1% and 13.5% of the 
regional market, respectively. The medical segment was the market’s most lucrative in 2005, 
generating total revenues of £3 billion, equivalent to 69.7% of the market’s overall value.  
 
Looking forward, the market is forecast to accelerate its current performance, with an anticipated 
CAGR of 10.1% for the five-year period 2005-2010 expected to drive the market to a value of £6.9 
billion by the end of 2010. The market’s growth will continue above the European growth which will 
only strengthen the United Kingdom’s position as the leader within the European biotechnology 
market. Its contribution to regional revenues is forecast to increase from 37.8% in 2005 to 38.9% in 
2010. 
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Projected UK Biotechnology Market, 2005-2010:  
Year Market Size (£ millions) % Growth 
2005 4.3 9.6 
2006 4.7 9.8 
2007 5.1 10.0 
2008 5.7 10.2 
2009 6.2 10.2 
2010 6.9 10.3 
Source: Datamonitor 
 
2.1.2 Healthcare and Bioscience as a Priority Sector in the East Midlands 
 
Estimates for the overall market size of the Healthcare and Bioscience sector in the East Midlands 
are difficult to specify, given the definitional difficulties associated with the industry (Standard Industry 
Codes are a poor basis for approximating the Healthcare and Bioscience sector given the variety of 
activities that contribute, without formal recognition, to Healthcare and Bioscience products, and 
there is no appropriate code for biotechnology). The structure of the Healthcare and Bioscience 
sector in the East Midlands covers all four main fields (pharmaceuticals, biotechnology, medical 
technology and specialist services). Whilst, there is a larger proportion in the medical technology and 
specialist services fields, the East Midlands is not considered atypical to the rest of the UK.  
 
Summary of the East Midlands Healthcare and Bioscience sector: 
 
 6.9% regional GVA (4th largest sector)* 
 9.7% regional employment (2nd largest sector)* 
 18% forecast employment growth, 2004-2014 (3rd highest sector)* 
 47% forecast output growth, 2004-2014 (4th highest sector)* 
 >250 medical technology companies employing over 19,000 people$ 
 >150 biotechnology and pharmaceutical companies employing over 12 000 people$ 
 8 NHS hospitals trusts (69 hospitals) and 22 NHS Primary Care Trusts (PCTs) employing 
108 000 people 
 6000 Healthcare and Bioscience researchers in academia 
(source *emda data for selection of priority sectors January 2006; $ Medilink EM database) 
 
 
These data clearly show the strong contribution Healthcare and Bioscience makes both nationally 
and to the East Midlands economy. By intervening strategically to support the Healthcare and 
Bioscience sector working in close partnership with industry, emda and other partners can help 
deliver key aspects of the East Midlands Regional Economic Strategy. 
 
 
3 Strategy for the Future 
3.1 Vision for the Sector 
To develop an internationally recognised, well networked, entrepreneurial bioscience and 
Healthcare and Bioscience community which has the skills, R&D infrastructure and access to 
finance and support that enables a broad range of businesses to flourish 
3.2 Partners’ Missions 
The sector has a broad stakeholder group, all of whom will be crucial to the successful 
implementation of any strategy to further develop the Healthcare and Bioscience sector in the region. 
 
3.2.1 BioCity 
 
BioCity is a specialist facility for Healthcare and Bioscience companies. BioCity’s vision is to become 
a major focus in the UK for Healthcare and Bioscience activities. BioCity’s goal is to build a profitable 
business by being instrumental in the development of a thriving bioscience industry in the East 
Midlands. It aims to achieve this by: 
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a) Becoming the central hub of bioscience activities for the East Midlands region through the 
physical and virtual location of companies on site; through the events created and hosted by 
BioCity; and through the networks it establishes; 
b) Building a strong brand associated with bioscience business success; 
c) Creating an efficient internal infrastructure to operate the facility, to provide services and to 
identify and roll-out new services; 
d) Reinvesting surplus funds in the regional bioscience industry. 
 
3.2.2 bioKneX 
 
bioKneX is the East Midlands Bioscience Knowledge Exchange. An organisation formed through 
collaboration between Nottingham Trent University, University of Nottingham and University of 
Leicester, with funding from the three Universities and emda. It is part of the Centre for Knowledge 
Exchange (CKE) Network which consists of over 20 centres across the country.  
 
bioKneX works with its funding universities and other organisations to promote the research base 
within the East Midlands. It works with Universities, Industry and Education to enhance collaborative 
and partnering potential, provide knowledge exchange opportunities and services and actively works 
on behalf of the East Midlands bioscience sector, showcasing regional excellence and innovation 
nationally and internationally. 
 
3.2.3 Medilink East Midlands 
 
Medilink EM is the specialist support organisation for the Healthcare and Bioscience sector in the 
East Midlands. As a membership based organisation Medilink EM represents over 120 fee paying 
companies. Medilink EM creates, draws together and shares knowledge in order to improve the 
market and business support opportunities of the regions Healthcare and Bioscience companies in 
three core areas: Business Networking, Business Support and Business Development. 
 
Medilink EM represents all parts of the East Midlands Healthcare and Bioscience community in 
dialogue and strategy development, with the aim of maximising the effectiveness of all the regional 
resources that are devoted to improving the performance of the sector. In addition, Medilink EM 
ensures that the East Midlands voice is fully presented in the formation of national strategies and 
programmes through links with national initiatives such as Medilink UK and the Department for 
Innovation, Universities and Skills (DIUS) funded Health Technologies Knowledge Transfer Network.  
 
3.2.4 East Midlands Incubator Network (EMIN) 
 
EMIN is a network of business incubators providing a package of business and technical assistance 
to start-up companies in the East Midlands. Through sharing best practice, EMIN is able to assure a 
high level of quality within these incubators. EMIN's mission is to increase the volume, value and 
survival rates of new start businesses in the East Midlands. The EMIN network incorporates virtual 
support with business space and incubator units throughout the region. EMIN does not have a sector 
specific focus, but does recognise healthcare as one of twelve business clusters as important to the 
region. 
 
3.2.5 East Midlands NHS Innovation Hub 
 
NHS Innovations East Midlands Hub is an NHS organisation that takes responsibility for advising 
NHS Trusts and members of staff on intellectual property and the commercialisation of ideas from the 
NHS.  The Hub is a membership based organisation with the Trusts across the East Midlands 
subscribing to access the expertise and networks provided by the Hub. 
  
The Hub has close ties to regional businesses and works with local companies to help develop and 
commercialise NHS inventions.  This also provides these companies with contacts within the NHS 
that are intended to promote the adoption of new devices by clinicians. The construction of these 
networks has been instrumental in the acceleration of new ideas into practice with a resulting 
improvement of patient care and also an increase in the level of awareness of local companies within 
the NHS procurement system. 
 
3.2.6 NHS  
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The new national health research strategy for the NHS Best Research for Best Health (BRBH) which 
was published in January 2006 sets out the contribution which the NHS will make to health research 
in England. The implementation of BRBH will see current single R&D contracts to NHS organisations 
replaced by a set of new funding mechanisms.  BRBH is therefore the focus for the development of 
research strategy within the NHS Trusts in the East Midlands. Currently the NHS Trusts are in the 
process of responding to initiatives within the BRBH Implementation Plans. Bids are being developed 
which build on their own and their research partners’ strengths with a view to developing a portfolio of 
research which will support the delivery of BRBH. Effective partnership working by organisations 
across the East Midlands will be essential to the success of R&D within the NHS. Future bids will 
build upon the partnerships underpinning the successful bids to be local co-ordinating centres for 
clinical research networks.  
 
The mechanism for allocation of funding to support research in the NHS is to be radically overhauled 
over the next two years. Current single NHS R&D contracts to Trusts will be replaced by a set of 
funding mechanisms, each designed to achieve the delivery of key components of the new national 
health research strategy Best Research for Best Health (BRBH). Key mechanisms for the allocation 
of funding will include: 
• Population based funding to support patients and health professionals participation in 
clinical research studies that are  adopted into a national portfolio of studies 
• Funding allocated on an open competitive basis for initiatives within BRBH to a large 
number of researchers across the country to undertake high quality research that will 
deliver the objectives of the strategy 
• Funding allocated on an open competitive basis to a relatively small number of 
organisations with outstanding international research teams to ensure that England 
remains at the leading edge of health research internationally 
 
3.2.7 UK Trade & Investment (UKTI) 
 
UKTI is the Government organisation that supports companies in the UK doing business 
internationally and overseas enterprises seeking to set up or expand in the UK. Its role is to help 
companies realise their international business potential through knowledge transfer, and on-going 
partnership support.  
 
To support its aim to "enhance the competitiveness of companies in the UK through overseas trade 
and investments; and attract a continuing high level of quality foreign direct investment", UKTI 
launched its new five year strategy ‘Prosperity in a Changing World’ on 20 July 2006. This sets out 
plans for the next five years on delivering our overarching aim. It states that, “The responsibility for 
facilitating international business growth and investment is shared among several government 
departments, the devolved administrations and the Regional Development Agencies (RDAs). We will 
ensure that all work together to avoid duplication or fragmentation and to get the best value for 
business. UK Trade & Investment (UKTI) is now taking the lead … to maximise the UK’s ability to 
attract FDI, win market share in the new high growth economies, and help business internationalise 
in a globalised world.” We will ensure that all work together to avoid duplication or fragmentation and 
to get the best value for business”.  
 
3.2.8 Higher Education Institutions (HEIs) 
 
The East Midlands has a wealth of higher education facilities across the region undertaking a full 
range of teaching, research and clinical activities. All of these areas provide a rich knowledge base 
for the region that should be accessible to Healthcare and Bioscience industry regionally as well as 
nationally and internationally. 
 
All HEIs provide a broad base of undergraduate study in the sciences and related disciplines as well 
as well-developed postgraduate research. Nottingham and Leicester both have medical schools and 
as such provide centres for clinical excellence. In addition, clinical activities in Derby and 
Northampton are well developed, making the region strong in clinical sciences. 
 
Nottingham Trent University (NTU) has developed close links with the Anthony Nolan Trust who are 
establishing their “Cell Therapy Centre in the East Midlands,” on the Clifton Campus of NTU.  
Supported by emda capital funding for the building, an investment of over £5 million pounds will be 
made by the Anthony Nolan Trust to establish the centre which will collect, process and store stem 
cells from placental blood to treat leukaemia and related disorders.  Key to this decision was the 
relationship developed over years with NTU and the support offered by the University Hospitals in 
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Nottingham and Leicester to the project. This represents just one of a number of examples of 
interactive projects undertaken between Universities in the region and the wider Healthcare and 
Bioscience community. 
 
Similarly, the East Midlands HEIs are strong in fundamental science across a wide range of 
Healthcare and Bioscience areas: forensics, pharmacy, clinical, new materials, nanotechnology, 
post-genomic technologies, biosciences, chemistry, drug discovery and drug development. These 
areas are cross-supported by regional strengths in Stroke, Cardiovascular, Neurology and Oncology. 
These are not intended to be exhaustive lists of competencies, however it is clear that East Midlands 
Universities have leading specialisms that support the development of the regions Healthcare and 
Bioscience sector.  Please see supporting material for a list of research groupings relating to the 
Healthcare and Bioscience sector and additional information collated by the East Midlands University 
Association (EMUA). 
 
3.2.9 emda  
 
East Midlands Development Agency (emda) is one of nine Regional Development Agencies in 
England set up in 1999 to bring a regional focus to economic development. The region’s shared 
vision is that by 2020 the East Midlands will be a flourishing region. A region made up of growing and 
innovative businesses, where skilled people are employed in good quality jobs, where we all feel part 
of healthy, inclusive communities and live in thriving, attractive places. 
This vision is underpinned by three main themes: 
 Raising productivity: enabling our people and businesses to become more competitive and 
innovative; 
 Ensuring sustainability: investing in and protecting our natural resources, environment and 
other assets such as infrastructure; 
 Achieving equality: helping all people to realise their full potential and work effectively 
together to enrich our lives and our communities. 
emda will ensure that the priority sectors (Transport Equipment, Construction, Food and Drink and 
Healthcare) are considered in the implementation of other actions in the RES to support growth, 
address skills needs and focus on efficiency and excellence. The priority sectors will require 
customised packages of specialist support to enable them to overcome barriers to growth and realise 
their full potential. Support will be directed towards an identified market failure or developmental 
bottleneck and will address both the shorter-term business requirements and the medium to long 
term innovation and development needs of the identified sectors. 
 
3.2.10 Private Sector 
 
The success of the implementation of this strategy will require input from the private sector as well as 
the various public sector support mechanisms. The exact nature of this input will be clarified as the 
strategy is delivered and also as the iNet develops. In the past, private sector input has been utilised 
to great success by Medilink in its Sub-Sector Strategy Groups, which have been instrumental in 
identifying the key themes of this document.
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4 Current Status of the Healthcare and Bioscience Sector in the East Midlands 
4.1 SWOT  
 
STRENGTHS         WEAKNESS 
 
Innovation 
 High quality University and 
NHS research base 
 High levels of R&D 
expenditure 
 Presence of innovative range 
of activities 
 Extensive product 
development 
 
Markets 
 UK market is one of the largest 
in the world 
 Strong presence in niche 
markets 
 Growing sector in sales, 
market share, employment 
 
Networks 
 A history of Healthcare & 
Bioscience in the region 
 Growing base of technology 
companies  
 Complementary engineering 
base in the region 
 Development of cross 
functional networks 
 
Infrastructure 
 Cost attractive central location 
in UK 
 BioCity as dedicated start-up 
facility for Healthcare & 
BioScience companies 
 Increasing support for new 
company start up: Biocity 
Germinator programme and 
Leicester University biobator 
facility 
 Development of additional 
science parks within the 
region (Nottingham University 
and Leicester Science Park) 
 Nottingham’s Science City 
status as a basis to build 
upon 
 
Access to Finance 
 Government committed to 
increased health expenditure 
up to 2008 
 
Skills 
 Availability of experienced 
staff (constrained by national 
shortage) 
 
Innovation 
 Competition between 
universities 
 Weak presence of non-
university R&D institutes 
 NHS is hugely bureaucratic 
and is inherently resistant to 
change. 
 No clear route for moving IP 
from research, through proof 
of concept to the market 
 
Markets 
 Niche market positions 
subject to technological 
change 
 The private healthcare sector 
remains underdeveloped. 
 
Skills 
 Weak entrepreneurial culture 
 Lack of critical mass of 
companies to build a 
sustainable and transferable 
pool of appropriately qualified 
staff 
 
 
Networks 
 Lack of high profile catalyst 
projects 
 Research & company base 
lacks connectivity 
 Limited support for start ups 
 
Infrastructure 
 Availability of 
sites/properties & planning 
permission 
 
Access to Finance 
 Lack of ‘Healthcare & 
Bioscience aware’ 
investors  
 
 
Innovation 
 Coordinated regional 
innovation strategy being 
developed and initiated 
 Increased ‘medicalisation’ of 
ailments 
 Greater R&D 
commercialisation including 
spinouts (University & NHS) 
 Greater use of university base 
 Drive to make NHS more 
receptive to new technology 
(NHS IP hub) 
 Establishment of the Anthony 
Nolan Cell Therapy Centre 
 
Markets 
 Regional NHS procurement 
hub just set up 
 Further development of niche 
market positions (regenerative 
medicine, nanotech) 
 Expansion of export 
performance 
 Increasing use of private 
companies to manage and 
operate Healthcare & 
Bioscience facilities. 
 Increased use of generics 
 
Skills 
 National NHS Knowledge & 
Skills Framework initiative as 
template for the region 
 Increased regional 
collaboration between industry 
and HEIs 
 
 
Infrastructure 
 Development of specialist 
facilities for drug 
development 
 Development of specialist 
facilities for alternatives to 
animal testing 
 Expansion of high quality 
science parks –move on 
space 
 
Access to Finance 
 EU  FP7 programme about 
to start – focus on SMEs 
 Government is keen to foster 
R&D expenditure 
 
Networks 
 re-structured NHS SHA  
 Inter-firm linkages 
 Linkages between sub-
sectors (biotech, pharma, 
Med Tech) 
 Stronger linkage between 
NHS, Industry and HEIs (via 
East Midlands NHS 
Innovation Hub, Medilink EM 
and bioKneX) 
 
 
 
 
 
 
Innovation 
 Innovative customers leave 
 Lack of start-ups undermines 
future expansion of the sector 
 NICE (National Institute for 
Health and Clinical 
Excellence) takes a long time 
to assess new products 
 Overhaul of NHS R&D 
funding 
 
Markets 
 Competition from other 
regions 
 Many hospital trusts facing 
financial deficits 
 Unknown NHS expenditure 
policy beyond 2008 
 Financial deficits facing the 
NHS and knock-on effects to 
future employment 
 
Skills 
 Not enough skilled scientists 
and business qualified staff to 
feed the growth of the sector 
 Support/training mechanisms 
insufficient to meet the needs 
of SME senior management 
 HEIs lag behind demand for 
new technology courses to 
feed the needs of new 
technology companies: i.e. 
nanobiotechnology. 
 
 
Networks 
 Regional and local agencies 
lose all credibility 
 
Infrastructure 
 High quality sites and 
incubators are not 
developed 
 
Access to Finance 
 Region’s SMEs do not 
attract required VC funding to 
drive start-up and/or growth 
 Other regions make it more 
attractive to invest there 
rather than in the East 
Midlands 
 Public funding has not 
previously been appropriately 
directed towards the 
Healthcare & Bioscience 
sector 
 
OPPORTUNITY        THREAT
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5 STRATEGIC PRIORITIES 
 
As a priority sector, Healthcare and Bioscience will require customised support to enable it to 
overcome barriers to growth and realise its full potential. The RES indicates that support will be 
directed towards identified market failures or developmental bottlenecks and will address both the 
shorter-term business requirements and the medium to long term innovation and development needs 
of the sector.  
 
The table on the following page highlights the needs, strategic priorities and tactical interventions 
identified for the sector, and notes to explain the table format are given below:  
 
Table Explanation 
Through surveys and other research a number of sectors needs have been identified and, based on 
these, Strategic Priorities have been developed, designed to address those needs. 
 
To deliver these Strategic Priorities, clearly defined, costed actions, or Tactical Interventions, are 
required. 
 
However, in a highly complex situation, there is no one-to-one relationship between Strategic Priority 
and Tactical Intervention; one Tactical Intervention could help to deliver many Strategic Priorities. 
 
Consequently a matrix has been developed in which owners are assigned to both Strategic Priorities 
and Tactical Interventions.  
 
The owner of the Strategic Priority is responsible for ensuring appropriate actions are taken to help 
implement it and that such actions are coordinated, while the owner of the Tactical Intervention is 
responsible for helping the owner of the Strategic Priority achieve his aims.  
 
The Strategic Priority has broad goals while the Tactical Intervention has sharp, clearly defined goals. 
 
It should be stressed that the ‘owner’ of each intervention is not necessarily the sole deliverer; 
rather it is likely that a group of stakeholders will be built around each intervention to ensure 
buy in and to leverage existing activities wherever possible. 
 
Inevitably the overall strategy will fail to address some needs that members of the sector feel are 
important, however the philosophy behind developing this plan has been to limit the number of 
interventions on the basis that it is better to do a small number of things well, rather than a lot of things 
poorly.  
 
The iNet is considered to be a valuable way of drawing together and delivering many of the Tactical 
Interventions set out in this plan. 
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A B C D E F G H I J K
NEED STRATEGIC PRIORITY MARKET FAILURE Provide targeted grant or loan 
funding towards specialist 
equipment
Increase the scope and support 
offered by Germinator/Biobator 
Programmes
Take the lead in ensuring 
accommodation is coordinated 
across region and needs are 
met
Provide an integrated regional  
Network for  Healthcare & 
Bioscience Knowledge 
Exchange 
Transform HEI business 
interaction through the 
appointment of deep sector 
specialist brokers that act 
across the entire research base
Drive the development of a major 
research facility within the region 
that will benefit business and 
academia alike
Improve access to European and 
national funding through a 
dedicated scheme
Lead and coordinate specialist 
business support infrastructure
Continuation of the regulatory 
affairs, clinical evaluation and 
NHS procurement networks
Healthcare & Bioscience specific 
training
Targeted support for overseas 
missions
OWNER BioCity BioCity BioCity bioKneX bioKneX bioKneX Medilink Medilink Medilink / NHS Inn. Hub Medilink UKTI
1 Knowledge of the regulatory 
environment
Support companies to overcome the 
regulatory barriers 
SMEs have difficulties understanding and 
negotiating regulatory barriers
Medilink Integrate regulatory training 
offerings into Germinator/Biobator 
programme
Link to regional & national 
initiatives
Guidance on regulations
Access to specialists
Training in European & US 
regulations & legislation, quality 
systems, staff roles, system 
operation, other specialist roles
Guidance service for appropriate 
international regulations
2 Knowledge of global healthcare 
markets
Facilitate access to the global market 
place 
Difficulty in accessing global healthcare 
markets
UKTI Provide market and technology 
information to support funding 
applications
Provide support that encourages 
SMEs to innovate in their 
approaches to markets:
Facilitate access routes into 
health services.
Establish strategic relationships 
with international quangos.
Help SMEs develop shared sales 
forces with other SMEs.
Supply chain events.
Guidance on regulations
Identification of NHS contacts, 
contracts, tenders & support with 
bids
Provide mechanism for 
assessment of health economics 
and technology for new ideas from 
a clinical, industrial and academic 
perspective
Provide market and procurement 
training
50% company subsidy for N. 
America / W. Europe focused 
support not covered by current 
UKTI policy.
3 1) Improve knowledge flow between 
organisations;
2) Increase inter-organisation trade;
3) Helps create and embed an 
entrepreneurial and innovative culture
Engineer sub-regional cluster growth to 
create a better environment for 
innovation
A self sustaining critical mass of 
businesses has not yet developed and so 
intervention is required to engineer this.
BioCity Target grants/loans to identified 
"hot spots"
Use Germinator/Biobator to 
increase the number & quality of 
innovation led companies within 
the "hot spots"and accelerate their 
initial development
Ensure accommodation for new 
& existing innovative companies 
is within identified hot spots
Target knowledge exchange 
activties to identified "hot spots"
Locate facility within one of the 
targeted hot spots
Link funding with development of 
centres of excellence where 
appropriate. 
Use EU funding to secure 
international supply chains for 
regional healthcare businesses.
Ensure support can be accessed 
from all "hot spot" locations
Target the provision of training into 
identified "hot-spots"
Use "Hot spots" to disseminate 
information
4 Improved product and process 
development through high quality 
provision of support with greater 
simplification and better strategic 
coordination
Coordinate the provision of specialist 
business support 
Underperformance in new product and 
process development.
Low adoption of innovation & under 
investment in research by SMEs
Medilink Use funding route to 
communicate available business 
support.
Germinator/Biobater will be one 
route by which specialist business 
support is accessed
Ensure accommodation is linked 
with business support outposts
Ensure knowledge exchange is 
integrated into wider business 
support and that both can be 
accessed from each other as a 
point of entry.
Provide access to HEI IP and 
process development 
capabilities. 
Increase access by SMEs to 
HEI infrastructure.
Ensure support appropriately 
linked
Ensure support is appropriately 
linked to other initiatives. 
LHT specialist to link companies 
with support provision including 
Business Link.
Provide support for healthcare 
product and process development 
via MAS+ programme
Support Business Intelligence on 
market size and value for 
innovative new product and 
process development.
Guidance & updates.
Ensure regulations are considered 
throughout product development
Product testing, clinical evaluation, 
& clinical trials 
Ensure support appropriately 
linked
5 Facilities appropriate to a company's 
stage of development
Coordination and development of 
accommodation and facilities.
The sector is not sufficiently well 
developed for private enterprise to be 
attractive to private enterprise to fill the 
gaps in the accomodation ladder. Neither 
will it look sufficiently far ahead to 
address future facilities needs.
BioCity Liaise with all agencies involved 
in developing strategic plans for 
sub regions. Ensure overall 
regional plan is developed
Provide access to HEI facilities, 
services and consultancy to 
address differing needs of 
SMEs. 
Provide input into company 
research needs to help plan 
future provision.
Coordinate with the development 
of other research-based facilities. 
Lead identifying the opportunity, 
raising funding and ultimate 
creation of facility.
Ensure that access to support is 
included where facilities are 
developed.
6 To take advantage of market 
opportunities 
Support companies to access high level 
business intelligence 
A failure to read market opportunities and 
market trends
Medilink Germinator/Biobator will be one 
route by which high level business 
intelligance is accessed.
Use business intelligence 
capabilities to suport companies 
in decision making with regard 
to knowledge transfer.
Maintain pool of specialist 
mentors & advisors.
Use business intelligence 
services including Globalwatch 
and Pera technology promoters to 
support exploitation of future 
market opportunities.
Provision of regulation updates & 
changes
Provision of NHS market 
intelligence
7 To raise the profile of the East 
Midlands Healthcare & Bioscience 
industrial & academic activities and 
thereby benefit local companies 
through improved recruitment, 
fundraising and revenue generating 
opportunities.
Coordinate and create a regional 
communication and marketing plan for 
EM Healthcare & Bioscience. 
No current coordinated regional brand for 
EM LHT leading to diffuse and ineffective 
message. Loss of opportunities to more 
established regions
Medilink Germinator/Biobater will be 
promoted in a coordinated way 
with other sector activities and will 
use common messages.
Ensure accomodation sites act 
as access points for delivery of 
message.
Ensure that all groups across 
the sector receive a consistant 
message 
use novel deep sector specialist 
approach to highlight activities in 
the region. 
Shout about regions successes
Ensure the chosen opportunity fits 
with the overall message on 
strengths in the region. Ensure 
development of the facility is fully 
exploited for marketing purposes.
Communication of what's 
available
Communicate the market to high 
net worth individuals outside the 
region
Promote all sector-related  training 
activities in a coordinated way. 
Single point of information for 
everything that's going on.
8 To make best use of the regional 
science base 
Promote exploitation of Technology and 
Know-How
A failure to leverage the science base
Difficulty accessing support from HEIs
bioKneX Target funding to support HEI-
business interaction
 Utilise knowledge exchange 
brokerage for Business- HEI 
interaction. 
Provide Innovation portal to 
increase frequency of HEI-SME 
collaboration
Use specialist brokers to 
Coordinate business HEI 
interaction to increase number 
of collaborations and access to 
EM knowledge base.
Integrate Academic and Industrial 
research within same facility. 
Economies of scale and increased 
synergy 
Use business support 
infrastructure to direct companies 
towards specialist support for 
access to new technologies.
Liaison with NHS & companies to 
facilitate access
Intellectual property management
Life science & healthcare 
entrepreneur action learning 
development programme
9 Sufficient levels of appropriately skilled 
and qualified personnel (repatriation 
and training) 
Build a high level skills base for the 
regions Healthcare & Bioscience skills
A lack of appropriately skilled and 
qualified personnel (repatriation and 
training) 
bioKneX Use Germinator to bring in 
management talent from outside 
the region
Map current and future regional 
skill gaps, define emerging 
technology needs and match 
with regional and national 
training provision. 
Increase regional industry 
experience pool. 
Use the facility to build on skills 
strengths in the region and 
contribute to addressing future 
needs.
Use company interactions to 
understand business training 
needs and feed into programme 
development
Consider regulatory training needs 
and incorporate into programme 
as necessary.
Lead the developmnent of a 
coordinated training programme 
that addresses priority needs in the 
sector (e.g. entrepreneurial 
development)
10 An understanding of available funding 
sources, how to deliver value on 
existing funding and how to make the 
business case for next round of 
funding
Increase access to and take up of 
funding for business growth and 
development 
A failure to access and use the available 
funding for innovation and lack of 
specialist funding sources
BioCity 50% loan/grant towards 
equipment (max £50k). Easy to 
access.
Use Germinator as one of the 
routes to access training in 
investment readiness.
Increase access to funding for 
collaborative R&D. Coordinate 
innovation funding to maximise 
ROI.
Use facility to draw in further 
funding for academic/business 
collaboration.
Provide access to expert 
organisations and personnel to 
support regional, national and EU 
R&D funds for innovative product 
and process development. 
Ensure companies are 
adequately informed of available 
funding opportunities. Link with 
existing schemes.
Link in with existing programmes, 
such as Connect InvoRed, to 
ensure sector specialist needs are 
met and supplement where 
necessary.
APPROXIMATE COSTS (PER ANNUM) Total cost: £2,805,000 £625,000 £200,000 £60,000 £120,000 £740,000 £60,000 £280,000 £155,000 £340,000 £225,000 TBC
iNet element £2,370,000 £575,000 £150,000 £40,000 £60,000 £530,000 £60,000 £280,000 £155,000 £340,000 £180,000
MEASURABLE OUTPUTS 10 companies supported each 
year
8 companies passing through 
Germinator each year. X 
companies through Biobater
Coordinating individual in place 
and recognised as such.
Single reference source for all 
property-related activities in the 
region affecting LHT.
regional R&D database 
completed. Increase network 
membership to 1000 registered 
members. Provide access to all 
EM LHT business and HEIs
Additional hires in place. 
Increased flow of SME 
collaboration opportunites to 
HEIs demonstrated. 
New hire in post. Stakholder 
engagement complete. Outline 
plans developed. 
10 companies supported each 
year
40-50 companies supported each 
year
30 companies supported each 
year.
120 people receiving training per 
year
30-50 companies supported per 
year (to be agreed with UKTI)
TIMESCALE FOR INTERVENTION Scheme established Q1 08.
First award Q2 08
Enhanced database in place Q4 
07. 
Sector specialists in place Q2 
08. 
Hire in place Q2 2008 First submission Apr 2007 Sept 07 start Jan-08 Jan 08 onwards
Jun 08 start entrepreneur 
programme
Jul-08
TACTICAL INTERVENTION- HELPS TO DELIVER THE STRATEGIC PRIORITY
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5.1 Strategic Priority 1: Support companies to overcome the regulatory 
barriers 
 
Owner- Medilink EM 
 
Need 
To get a product, process or service to market requires an understanding of the regulatory 
requirements throughout the full development pathway from concept to penetrating the 
market.  The life science and health technologies sector is heavily regulated and both the 
regulations and the ability to interpret them correctly are key to increasing the number of 
products entering the market (ref HITF report Nov 2004). The situation is complicated further 
by different regulations and Authorised Bodies in the various global markets. 
 
Market Failure 
A lack of resource and skills within SMEs often results in a focus on the day to day business. 
This in turn means that regulatory requirements are becoming secondary considerations, 
which can result in a failure to understand or keep up to date with regulations, missed 
opportunities, or inappropriate regulatory conformance routes being taken for a target market. 
These issues particularly occur because an SME’s regulatory role is often carried out by 
somebody with a multitude of other tasks and management do not appreciate what it means 
to the company. 
 
 
Intervention 
A network for accessing regulatory requirements, updates and specialist help has been 
developed.  The following tactical interventions will ensure that SMEs become more 
‘regulation aware’ and remain so: 
(B) Integrate regulatory development support into Germinator/Biobater programmes 
(H) Link to national and regional business support 
(I) Continuation of the regulatory affairs network (which is currently due to stop in July 
2007) to provide up to date guidance and access to specialists. 
(J) Training in global regulations and legislation 
(K) Targeted support for international trade – guidance on appropriate regulations 
 
 
5.2 Strategic Priority 2: Facilitate access to the global market place 
 
Owner- UKTI 
 
Need 
Within the UK the NHS remains the largest market for Healthcare and Bioscience products 
and services. It is estimated that the NHS expenditure on goods and services is in excess of 
£15 billion which represents a significant opportunity to regional business assuming they 
understand the access routes. 
 
Globally, emerging markets are generally not the main focus of Healthcare and Bioscience 
SMEs because of resource issues and the availability of easier wins in key Western markets. 
With the USA constituting the largest world market for medical devices, c. 40%, and the 
European market, at c.32% is the second largest market1, these are the main focus of the 
majority of Healthcare and Bioscience SMEs.  
 
Market Failure 
NHS purchasing is often not about the best products being bought.  This is precipitated by 
established companies having the resources to interact with the NHS at all levels whereas 
                                                     
1 MEDICAL DEVICES COMPETITIVENESS AND IMPACT ON PUBLIC HEALTH EXPENDITURE, Study prepared for the 
Directorate Enterprise of the European Commission July 2005 
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SMEs often do not. Therefore, the benefits of innovations may not reach the market, even if 
the product is, by whatever measure, better. 
 
A focus on the USA and Western European markets is strategically important to help the 
Healthcare and Bioscience sector’s SMEs grow. Not least amongst the reasoning for greater 
liaisons with the USA is the fact that this is a potential source of investment funding to help 
Healthcare and Bioscience businesses move forward. UKTI provide valuable support to 
companies looking to undertake international trade and continued collaboration with all 
partners will continue in support of the recently published national strategy2. However, a focus 
on emerging markets and making good exporters better could result in some SMEs, who 
need support to succeed in international markets, not being sufficiently supported. 
 
Strategic Intervention 
This strategy intervention is primarily delivered by the following Tactical Interventions: 
(G) Market trend and foresight analysis to support R&D applications 
(H) Encourage SMEs to innovate in market approaches and facilitate access to 
global health service markets. 
(I) Provide mechanisms for assessment of technology and health economics 
and facilitate access to NHS. 
 (J) Market understanding and procurement training  
(K) Support for international missions 
 
 
5.3 Strategic Priority 3: Engineer sub-regional cluster growth to create a 
better environment for innovation 
 
Owner- BioCity  
Need 
Companies benefit significantly from being within a critical mass of similar and related 
organisations (ref Porter). This has been further supported by the experience at BioCity in 
Nottingham. Critical mass: 
a) improves knowledge flow between organisations; 
b) increases inter-organisation trade; 
c) helps create and embed an entrepreneurial and innovative culture. 
 
Furthermore, once a critical mass is achieved, the sector can develop a self-sustaining 
upward spiral.  
There is a need therefore to build on the start that has been made within the region and to 
drive the creation of a critical mass of businesses in the sector. 
 
Market Failure 
Once a critical mass of organisations in the sector has been reached it becomes self 
sustaining and continues to grow unaided. However, until that point is reached, active 
intervention is required as the marketplace is not sufficiently well developed to achieve this at 
the current stage. The evidence for the fact that critical mass has not yet been reached is 
demonstrated in many ways, for example: 
 Limited dedicated and/or suitably skilled resource within professional services firms; 
 No private sector activity in the development of facilities for life and health 
technology companies; 
 Low level of investment or attention from investors outside the region; 
 Limited management talent and the fact that a significant number of senior 
executives in local Healthcare and Bioscience businesses do not live in the region 
 
Strategic Intervention 
The most efficient and effective route to achieve this is, logically, to focus resources on 
particular “hot-spots” within the region.  
This Strategic intervention is primarily delivered by the following Tactical Interventions: 
                                                     
2 Prosperity in a changing world, UK Trade and Investment, 2006 
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(B) Germinator/Biobater- increasing the number and quality of new businesses; 
(C) The development of facilities and accommodation; 
(F) Development of a major research centre; 
(J) Skills improvement. 
 
5.4 Strategic Priority 4: Coordinate the provision of specialist business 
support 
 
Owner- Medilink EM 
 
Need 
The translation of knowledge into commercially successful products, processes or services is 
a key challenge to SMEs (ref Regional Innovation Strategy and Action Plan) to ensure they 
innovate and do not rely too heavily on old products or processes for their success. 
   
Market Failure 
Only 4% of turnover from East Midlands businesses is attributable to new or improved 
products in the East Midlands, compared with a UK national average of 9% (ref RES 
evidence base). Empirical evidence shows a positive correlation between levels of innovation 
and economic performance and literature clearly demonstrates a benefit (ref OECD 2001):  
 1% increase in business R&D leads to 0.13% increase in multi-factor productivity 
(MFP) 
 1% increase in foreign R&D leads to 0.44% increase in MFP 
 1% increase in public R&D leads to 0.17% increase in MFP 
  
Intervention 
To ensure successful commercialisation, specialist support, provided by those with 
experience of the sector, is needed from the initial concept idea, through development, to 
market exploitation. This strategic priority will therefore impact on all Tactical Interventions: 
(A) Communicate available specialist business support through targeted funding 
initiatives 
(B)  Germinator/Biobator – provide access routes to specialist support 
(C) New facilities must ensure access to specialist support 
(D)  Knowledge exchange as an integrated component of support 
(E) Access to HEI capabilities 
(F)  New facilities must ensure access to specialist support 
(G) Link to funding for R&D   
(H)  Healthcare and Bioscience specialist will link SMEs to available support initiatives  
(I)   Integrate regulations in to product and process development 
(J)  Facilitate product testing, clinical evaluation, and clinical trials 
(K)  Ensure product and process development is appropriate to global market 
 
 
5.5 Strategic Priority 5: Coordination and development of 
accommodation and facilities 
 
Owner- BioCity  
 
Need 
If companies are to grow and succeed, they need affordable facilities that are appropriate to 
their stage of development. If early stage and start up facilities are not available, the number 
of companies within the region will inevitably be less than it otherwise could be. Similarly, 
once established, companies will need to be able to expand into appropriate accommodation 
within the region otherwise they could be lost to areas where such accommodation is 
available. 
 
Market Failure 
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Within the East Midlands, the sector is not yet sufficiently developed to encourage private 
enterprise to invest in the development of property for this sector on a speculative basis. 
Moreover, the provision needs to be coordinated and planned many years ahead of the need 
to ensure facilities are available at the appropriate time; this is not something that market 
forces will do. 
 
Strategic Intervention 
A single organisation will lead the coordination and development of accommodation and other 
facilities for Healthcare and Bioscience businesses within the region. The primary role will be 
to ensure that potential gaps in the Healthcare and Bioscience property ladder are considered 
in future developments in key locations by becoming embedded within the network of 
organisations involved in property-related initiatives in the region. Secondary roles will include 
influencing the nature of the provision, for example, the integration of business support 
activities at the location. 
 
5.6 Strategic Priority 6: Support companies to access high level 
business intelligence 
 
Owner- Medilink EM 
 
Need 
In order to take advantage of market opportunities, a company needs to understand the 
structure of that market, the drivers behind the market, the size of the market, future trends in 
the market. SMEs do not utilise market intelligence because of a number of factors, including 
not understanding the importance of the data, not being aware of the available information 
sources, costs of such information can be prohibitive to SMEs.  
 
Market Failure 
A failure to read market opportunities and market trends can result in loss of business. There 
are a number of theoretical sources of market failure which would be expected to affect the 
costs of acquiring information necessary to inform international marketing strategies and the 
costs of overseas market entry.  These are: 
 Under provision of public goods: private-sector market incentives are generally 
insufficient to provide optimal quantities of public goods.  
 Network and intermediation failures: social networks and intermediaries 
underpin international linkages and knowledge flows, and enable businesses to 
identify and gain access to overseas contacts and opportunities.  
 Informal barriers to market access: issues arising in the practical implementation 
of rules for international trade and investment systems, or other less formal barriers 
such as .technical standards 
 Weaknesses in internationalisation skills: market failures affecting the supply of 
internationalisation skills in the economy may limit their availability, particularly for 
young businesses. It may be necessary for firms to build up these skills internally to 
a significant extent, rather than buying them in.  Weaknesses in internationalisation 
skills are likely to increase the costs of entering overseas markets as a result of 
pursuing sub-optimal marketing research and market strategies which waste 
resources. Since longer- established firms might be expected to have developed 
these skills, such weaknesses may particularly affect the performance of young 
innovative companies3. 
 
Strategic Intervention 
This strategic intervention is primarily delivered by the following Tactical Interventions: 
(B) Germinator/Biobator – provide access to information 
(D) Intelligence for technology transfer decision making 
(H) Use of information, mentors & advisors to enable future market exploitation 
 (I)  Regulatory and NHS market intelligence for informed decision making 
                                                     
3 DTI ECONOMICS PAPER NO.18, International Trade and Investment – the Economic Rationale for Government Support, 
JULY 2006 
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(K) Global market information - current position and future trends 
 
5.7 Strategic Priority 7:  Coordinate and create a regional 
communication and marketing plan for East Midlands Healthcare and 
Bioscience 
 
Owner- Medilink EM  
Need 
Healthcare and Bioscience is a priority sector for the East Midlands. As such it has been 
identified as being of significant potential in raising many of the identified underperforming 
indicators within the region (see RES). In order for the region to accelerate the development 
of the Healthcare and Bioscience sector it is vital that the profile of Healthcare and Bioscience 
is raised. 
 
Market Failure 
There are many notable successes within the EM Healthcare and Bioscience sector. However 
these achievements are not used effectively in underpinning the accelerated development of 
the sector. Likewise there is currently no coordinated consistent message that collectively 
highlights the East Midlands as a region of high quality science and innovative commerce. 
The lack of focus in developing a regional Healthcare and Bioscience plan means that 
opportunities that should come to the region are lost to other regions where a more integrated 
Healthcare and Bioscience sector is perceived. 
Furthermore, it is critical to the successful creation of an effective pipeline of commercial 
entities that there is effective communication within the region to ensure that people are 
aware of the opportunities and support mechanisms available.  
It is not sufficient to adopt a passive communication strategy, as this will not support the 
desired sector development in the required timeframe. 
     
 
Strategic Intervention 
There is a critical need to bring together all aspects of EM Healthcare and Bioscience  to 
create an effective sector communication strategy. The strategy will be centred on 
coordinating the message of an integrated Healthcare and Bioscience region that can 
demonstrate the successes and highlight the opportunities that exist within the region. 
    
This Strategic intervention is primarily delivered by the following Tactical Interventions: 
(D) Germinator/Biobater- increasing the number and quality of new businesses; 
(E) The development of facilities and accommodation; 
(F) Provide an integrated network for Healthcare and Bioscience Knowledge exchange 
(G) Increase the breadth and depth of HEI-business interactions through targeted 
knowledge exchange brokerage. 
(G) Development of a major research centre; 
(H) Improve access to EU and National funding. 
(I) (H) Improving knowledge of existing funding through business support routes- 
ensuring coordination with existing initiatives such as GINEM; 
(K) Skills improvement. 
 
5.8 Strategic Priority 8:  Promote exploitation of Technology and Know-How. 
Owner- bioKneX 
 
Need 
Increasing innovation within the region’s companies is a key target of East Midlands 
Innovation and RES (see RES and Regional Innovation Strategy and Action Plan). While 
there are a number of complementary approaches that will be utilised to achieve this, 
arguably the most important is to increase access to innovative technologies and processes. 
Such access can either come from B-2-B interaction or from HEI-business interaction. While 
critical mass in the commercial sector is low at present within the region, the HEI network of 8 
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Universities along with a larger number of FEIs is strong but not utilised to its fullest extent. 
Developing new paradigms for HEI-business interaction is a central theme of the Regional 
Innovation Strategy and Action Plan. 
 
Market Failure 
Regional Innovation Strategy and Action Plan has identified HEI-business interaction and 
particularly SME interaction as being a market failure. This means that the Science base 
within the region is not being effectively utilised by the regions SME community. There are 
several areas where this failure manifests itself; Shortfall in skills training for industry, access 
to facilities and services that would accelerate businesses developing and access to 
intellectual property to drive value creation and thereby generate inward investment.   
 
Strategic Intervention 
Current ways of working do not give the desired levels of HEI-SME interaction in a way that is 
cost effective and appropriate for SMEs at different stages of their development. In order for 
this to be addressed there needs to be a change in the way HEIs and SMEs interact. This is a 
key component of the Innovation strategy and seeks to establish more effective pathways to 
achieve increased levels of innovation and make EM Healthcare and Bioscience companies 
more competitive. This will be achieved through the Knowledge Exchange and other 
mechanisms to provide targeted knowledge exchange brokerage to ensure the regions SME 
community has access to the right facilities, services and technology transfer. This has 
obvious additional benefit to the HEI community by increasing collaboration potential and 
access to additional funding. 
 
 
5.9 Strategic Priority 9:  Build a high level skills base for the region. 
 
Owner- bioKneX 
 
Need 
With an increasing number of high technology Healthcare and Bioscience companies setting 
up in the region there is a need for parallel increase in the number of skilled individuals to 
build and run them. Both Commercially and Technically qualified and experienced personnel 
are required to drive the growth of the sector moving forward: 
   
a) To meet the new technology needs of future companies, the region will need to 
access Science, Engineering and technical staff with the appropriate technical 
scientific and industrial backgrounds; 
b) Experienced senior management and commercial business development 
professionals are required to take start up companies from inception to SME status 
and beyond. 
 
Market Failure 
The Leitch review of skills4 concluded that the ‘UK’s skills are not World class’ and that this 
could potentially limit economic development. The East Midlands has not historically been 
recognised as a centre for Healthcare and Bioscience industry. With a few notable exceptions 
the sector’s SMEs are small and early in their development. This means that attracting 
experienced senior professionals to the region has been difficult and retention within the area 
is unlikely unless there are new opportunities that retain experienced staff within the region. 
 
HEIs play a key role in the provision of skills training to industry and the NHS, and will be an 
important factor in building a high level skills base. The Strategic Health Authority (SHA) also 
plays a significant role in training provision and, guided by National agendas, sets local 
priorities. In addition, Skills for Health and Skills for Care have important roles to play in 
determining the strategy for the modernisation of education. 
 
                                                     
4 Leitch Review of Skills ‘Prosperity for all in the global economy – world class skills’, December 2006, HM Treasury report. 
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For the Healthcare and Bioscience sector to achieve its potential, technical staff are needed 
in greater numbers and, in order to retain them within the region, there needs to be sector 
critical mass. Without such critical mass, personnel will not have job opportunities in the 
region (circulating staff) and hence will be pulled to regions with more established Healthcare 
and Bioscience sectors. 
More accurate skill gap information is needed to guide HEI course construction and content 
as well as course type: vocational vs. academic and scientific vs. technical.  
 
Strategic Intervention 
The provision of a skilled Healthcare and Bioscience workforce is a priority for the sector. This 
will be achieved through defined tactical interventions as detailed below.  
 
(B) Germinator/Biobater- increasing the number and quality of new businesses; 
(D) Provide an integrated network for Healthcare and Bioscience Knowledge 
exchange 
(E) Increase the breadth and depth of HEI-business interactions through targeted   
knowledge exchange brokerage. 
(F) Development of a major research centre; 
(H) Business Support 
(I) Skills improvement regulatory. 
(J) Healthcare and Bioscience specific training 
 
5.10 Strategic Priority 10: Increase access to and take up of funding for 
business growth and development 
 
Owner- BioCity  
 
Need 
There is still insufficient investment flowing into Healthcare and Bioscience companies in the 
region, evidenced through company surveys and in comparison to other technology centres 
such as Cambridge. This stems from two key deficiencies: 
c) A shortfall in the absolute level of funds available to companies in the region; 
d) Companies lack of knowledge and failure to access those funding streams that are 
available, both private and public. 
 
Market Failure 
Because the sector in the region is not sufficiently well developed companies have difficulty 
gaining the attention of large specialist investors. Furthermore, banks have trouble 
understanding the businesses and are often reluctant to lend to start up technology 
companies.  
In addition, small companies with limited resources have trouble understanding the range of 
public funding available, and accessing it is often perceived to be overly complex, especially 
EU funding.   
 
Strategic Intervention 
The intervention focuses on strategies designed to increase both the availability of funding to 
companies in the sector, but also increase the take-up of funding that is already available.  
 
In particular, this Strategic Intervention is delivered by the Tactical Interventions concerning:  
(A) The creation of a specialist grant/loan fund; 
(J) Increasing access to European Funding; 
(K) Improving knowledge of existing funding through business support routes- ensuring 
coordination with existing initiatives such as GINEM; 
(J) Improving training and skills of management. 
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6 TACTICAL INTERVENTIONS 
 
6.1 Tactical Intervention A: Provide targeted grant or loan funding to 
support investment in innovation 
 
Owner - BioCity 
 
Description 
A fund will be established which would provide grants or, ideally low interest loans, to SMEs 
that are investing in high technology equipment to expand or improve the productivity of their 
business. The grant/loan would be of an amount that is significant to the company, for 
example £50,000, and would contribute up to 50% of the cost of the equipment. It is possible 
that this funding could be further linked to the requirement for collaboration and it could be 
geographically targeted to drive sub-regional clustering. 
 
The loan model is preferred in order to make the fund as evergreen as possible. It is 
envisaged that there would be a two year interest free period after which the company would 
be required to repay the loan within two years and incur interest at a percentage above bank 
base rate. 
 
Delivery 
The fund would be managed by BioCity who would employ a manager to promote the fund, 
process applications and manage the relationship with the company on an ongoing basis. 
 
Cost & Funding 
Up to ten loans of up to £50,000 would be made each year for a total of £500,000. In addition, 
a manager’s salary and overhead would need to be paid at £50-£70,000, and overheads of 
£55,000. 
 
This programme is very much aligned to the Innovation strategies of “Delivering High Quality 
Innovation Support” and “Fostering enabling and Emerging Technologies” by encouraging 
SMEs to invest in new equipment and adopt new technologies. 
 
For the first three years it is envisaged that this would be funded through the iNet, after which 
point BioCity would underwrite any shortfalls in the annual fund due to bad debts and cover 
the cost of the manager. 
 
Outcomes 
The primary outcome will be the support of up to 10 companies per annum to invest in new 
equipment that will improve the performance of their business. This links to the following RES 
Strategic Sub Priorities  
2d- Overcoming barriers to SME growth 
3a- Increasing investment in R&D 
3b- Helping Existing Businesses Deploy Technologies and Processes 
3c- Resource efficiency through effective use of technology and management practices 
3d- Translating scientific excellence into business success 
3e- Growing the region’s key sectors 
 
Strategic Priorities Affected 
(3) Engineer sub-regional cluster growth 
(4) Provision of specialist business support 
(10)Increase access to and take up of funding 
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6.2 Tactical Intervention B:  Increase the scope and support offered by the 
Germinator and Biobater programmes 
 
Owner - BioCity 
 
Description 
The Bioscience Germinator is currently running as an ERDF funded pilot project in 
collaboration with Nottingham Trent University and The University of Nottingham. The 
programme is designed to work with very early stage business opportunities and accelerate 
their development by providing a range of business support including a hands-on, part time 
manager to drive the business forward. The programme started in May 2006 with a target of 
supporting 4 companies at a time, however demand is such that 5 companies signed up to 
the scheme by October 2006. The aim of the scheme is to: 
1) accelerate the development of start up businesses 
2) improve their quality and set them on a firm footing; 
3) act to draw through more opportunities and thereby encourage entrepreneurial 
activity, particularly in academic researchers. 
 
The Biobater is a Leicester University initiative which operates in the area slightly before that 
of the Germinator, encouraging academics to come forward with commercial opportunities 
and supporting them in the early development of these. 
 
In both cases resources limit the geographical scope (Germinator can only operate in 
Objective 2 areas) and the volume of activity. It is already becoming clear than an expansion 
of the resources available to these operations could have a significant impact on output. 
 
Delivery 
BioCity currently delivers the Germinator pilot and it is proposed that BioCity will work in 
collaboration with NTU and Leicester, Nottingham and Loughborough Universities to further 
expand and coordinate the Germinator and Biobater. 
 
Cost and Funding 
The Germinator pilot is relatively cost efficient and could be significantly expanded for 
approximately £200,000 per annum. This programme fits within the Innovation strategies of 
“Delivering High Quality Innovation Support” and “Fostering enabling and Emerging 
Technologies” by encouraging the successful development of new, innovative companies. 
Consequently it is envisaged that £150,000 of the annual funding would be from the i-Net and 
£50,000 from BioCity/ERDF. 
 
Outcomes 
The Germinator would support 8 companies per annum in their initial phases of development 
(24 over three years). Each of these companies would be expected to create an average of 
two new jobs over the period, i.e. 48 new knowledge-based jobs. 
This Tactical Intervention links to the following RES Strategic Sub Priorities  
2d- Overcoming barriers to SME growth 
3a- Increasing investment in R&D 
3d- Translating scientific excellence into business success 
3e- Growing the region’s key sectors 
 
Strategic Priorities Affected 
(1) Support companies to overcome regulatory barriers 
(3) Engineer sub-regional cluster growth 
(4) Provision of specialist business support 
(6) Access to high level business intelligence 
(7) Regional communications and marketing  
(9)  Build high level skills base 
(10)Increase access to and take up of funding 
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6.3 Tactical Intervention C: Take the lead in ensuring accommodation needs 
of the sector across the region are met 
 
Owner - BioCity 
 
Description 
There are many initiatives currently looking at technology-based employment accommodation 
across the region as well as studies to consider future demand. Although there is 
communication between the various elements, there is no single organisation or individual 
that is considering how the jigsaw fits together as a whole. Consequently there is a risk of 
opportunities or needs being missed or, conversely, duplicated. 
This role requires initial work to pull together all existing initiatives to enable the big picture to 
be seen and then on an ongoing basis become networked into these and future initiatives to 
ensure the picture remains current. In addition, there will be a need to seize opportunities for 
Healthcare and Bioscience -related employment land as and when they become available so 
as to secure them for future development within the “hot-spots”. 
 
Costs and Funding 
This would require a half-time post with an estimated cost of £60,000, including overheads.  
The intervention is aligned with the Innovation Strategy for the Region, in particular “Creating 
an Effective Environment for Innovation”, consequently it is envisaged that this post would be 
2/3 funded through the iNet and 1/3 from BioCity. 
 
Outcomes 
The primary outcomes would be: 
(a) Establishment of a structure for the coordinated development of Healthcare and 
Bioscience accommodation in the region with a figurehead to lead it; 
(b) A pulling together in a single point of reference all existing property-related 
initiatives that impact the Healthcare and Bioscience sector. 
 
The following RES sub strategies are impacted: 
  2d Overcoming the barriers to SME growth 
  3e Growing the region’s key sectors 
  7a Development Land 
 
Strategic Priorities Affected 
 (3) Engineer sub-regional cluster growth 
 (4) Coordinate the provision of specialist business support 
 (5) Coordination and development of accommodation and facilities 
 (7) Regional communication and marketing 
 
6.4 Tactical Intervention D: Provide an integrated regional network for 
Healthcare and Bioscience knowledge exchange. 
 
Owner - bioKneX 
 
Description 
In order for The EM Healthcare and Bioscience sector to develop innovative products and 
processes, the various parts of the sector both public and private need to work in conjunction 
to provide an infrastructure that will provide mechanisms for effective knowledge exchange. 
Three of the EMs HEIs have already established bioKneX as the principle knowledge 
exchange organisation for East Midlands bioscience. This Higher Education Funding Council 
for England (HEFCE) funded organisation has also attracted EU funding from emda and is 
seen as an exemplar of best practice in the utilisation of IT systems in this area (EU and 
Independent consultation). It has established a network of over 600 members representing; 
Major companies, SMEs, support organisations, HEIs, schools and individuals. 
The further development of this network is a critical component of providing enhanced 
knowledge exchange opportunities to companies and researchers within the region. 
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Delivery 
The further development and maintenance of the network will be undertaken by bioKneX. 
Through this network, the regions Healthcare and Bioscience needs are addressed on 
multiple fronts, and its aims and objectives fit closely with those of the Innovation strategy and 
establishing the healthcare iNet. 
  
Cost & Funding 
The construction and operation of the knowledge exchange network was part financed 
through EU funds and is maintained by bioKneX through HEFCE funding. In order to expand 
this activity there is a critical need for additional business development staff. Part of this would 
best serve the iNet if it were a joint post with one of the other delivery organisations, most 
probably NHS Innovation Hub, or Medilink, and would become a core component of the iNet. 
 
One fully overheaded FTE (Full time equivalent) £60,000 provided by bioKneX.  
One fully overheaded FTE £60,000 as a joint post  
    
   
This programme is very much aligned to the Innovation strategies of “Delivering High Quality 
Innovation Support” and “Fostering enabling and Emerging Technologies” by encouraging 
closer collaboration between SMEs and HEIs and providing knowledge exchange support. 
 
Outcomes 
The primary outcomes would be: 
(a) The primary outcome will be the support of the Innovation strategy and 
enhancing the access to knowledge exchange processes across the region. 
(b) Access to sector specific knowledge  
(c) Closer alignment of industry needs with HEI capabilities and capacity.   
 
This links to the following RES Strategic Sub Priorities:  
2d- Overcoming barriers to SME growth 
3a- Increasing investment in R&D 
3b- Helping Existing Businesses Deploy Technologies and Processes 
3c- Resource efficiency through effective use of technology and management practices 
3d- Translating scientific excellence into business success 
3e- Growing the region’s key sectors 
 
 
Strategic Priorities Affected 
(3) Engineer sub-regional cluster growth 
(4) Coordinate the provision of specialist business support 
(6) Support Companies to access high level business intelligence 
(7) Coordinate and create a regional communication and marketing plan  
(8) Promote Exploitation of technology 
(9) Build a high-level skills base for region 
 
6.5   Tactical Intervention E: Increase the breadth and depth of HEI-business 
interaction through targeted knowledge exchange brokerage. 
 
Owner - bioKneX 
 
Description 
To transform the way businesses and academic centres interact, we propose a radical new 
approach which involves the appointment of a small number of roving deep-sector specialists 
in technology brokering.  
 
No single institution within the region can justify the cost of an expert in a particular field who 
is able to maintain a thorough understanding of both the research base and the industrial 
base in that area. Historically therefore, technology transfer offices have needed to appoint 
 21 14/06/2011 
generalists who have to work across a wide range of fields and inevitably cannot develop the 
required depth of knowledge to be fully effective. However, by spreading that resource across 
the institutions in the region, it is possible for such expertise to be built up.  
 
It is proposed that deep sector specialists would be appointed in fields where there is real 
strength in a number of institutions, for example drug delivery, and they would be responsible 
for (a) understanding industry needs and translating that to academic researchers and (b) 
gaining a thorough understanding of the academic asset base in their field and translating that 
to their corporate base. They would know exactly who was doing what in their particular 
industry and who the key individuals are, and likewise with academia. 
 
Delivery 
bioKnex would work with the Universities and research centres in the region to identify the 
areas of focus based on the key research strengths. It would then drive the recruitment of the 
specialists and coordinate and manage their activities. 
 
Cost and Funding 
Provision of this targeted intervention would require the following headcount with additional 
FTE distributed across the regions HEIs. This targeted intervention falls under both the 
innovation strategy and bioKneX’s current core activities therefore;   
 
One Senior Manager, fully overheaded, funded through bioKneX   £90,000 
Two FTE, fully overheaded, funded through bioKneX        £120,000 
Three FTE, fully overheaded, funded through iNet.    £190,000 
Four FTE (8x0.5FTE) fully overheaded within HEIs funded through iNet    £240,000  
Operational cost          £100,000 
 
Outcomes 
Primary outcomes would be:  
(a) To create a robust HEI-SME interface mechanism that allows greater access 
for SMEs to HEIs. 
(b) Provide a pipeline of HEI-SME collaborative/commercial opportunities for 
further action by HEIs and companies.  
(c) Increase the number of EM companies accessing HEI services, facilities and 
Intellectual Property (IP). 
(d) Through brokerage, increase access by SMEs to Grants for Research and 
Development and other funding which enables HEI research participation. 
 
This links to the following RES Strategic Sub Priorities: 
  
2d- Overcoming barriers to SME growth 
3a- Increasing investment in R&D 
3b- Helping Existing Businesses Deploy Technologies and Processes 
3c- Resource efficiency through effective use of technology and management practices 
3d- Translating scientific excellence into business success 
3e- Growing the region’s key sectors 
 
Strategic Priorities Affected 
 
(3) Engineer sub-regional cluster growth 
(4) Coordinate the provision of specialist business support 
(5) Coordination and development of accommodation and facilities 
(7) Coordinate and create a regional communication and marketing plan  
(8) Promote Exploitation of technology  
(9) Build a high level skills base for region  
(10) Increase access to funding for growth and development 
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6.6   Tactical Intervention F: Drive the development of a major research 
facility within the region that will benefit academia and business alike. 
 
Owner - BioKnex 
 
Description 
In order to stimulate innovation and cross sector participation it is vital that current evidenced 
barriers to closer working are overcome. This is an approach that has been used in industry 
to advantage, e.g. GlaxoSmithKline’s reorganisation to Centres of Excellence in Drug 
Discovery (CEDDs). This is an innovative approach and has compelling features for driving 
innovation within the EM Healthcare and Bioscience sector. There are a number of possible 
routes through which such a cross-functional facility could be achieved; either developed 
along a defined technology need such as the Eminate facility in Nottingham, or on a sector 
strength basis such as medical devices or drug delivery, or to coordinate the clinical research 
expertise of the region’s hospitals, Primary Care Trusts (PCTs) and HEIs. However, 
irrespective of the form, the advantages of developing a regional centre of excellence are 
compelling. Such a facility would bring academic researchers into direct contact with business 
on a daily basis; providing opportunities for mutual knowledge and know-how transfer and 
economies of scale in facilities management and utilisation. This would also provide a 
platform for attracting further funding and enhance opportunities for collaboration. In addition 
it would feed future skills needs and provide a ready market for new graduates, which would 
aid skills retention within the region. 
        
Costs and Funding 
Initial scoping of this targeted intervention would require one FTE to manage the process of 
Project scoping, fund identification, location selection and project management of the ongoing 
process. 
The fully overheaded cost for one FTE would be £60,000. 
The intervention is directly aligned with the Innovation Strategy for the Region, in particular 
“Creating an Effective Environment for Innovation”, consequently it is envisaged that this post 
would be funded through the iNet. 
 
Outcomes 
The primary outcomes would be: 
(a) Develop plans for a major regional research centre that would benefit both 
Academia and Business alike and generate synergies for innovative working 
processes. 
(b) Identify suitable locations and funding to progress development of a combined 
regional research and development centre.  
 
The following RES sub strategies are impacted: 
2d- Overcoming barriers to SME growth 
3a- Increasing investment in R&D 
3b- Helping Existing Businesses Deploy Technologies and Processes 
3c- Resource efficiency through effective use of technology and management practices 
3d- Translating scientific excellence into business success 
3e- Growing the region’s key sectors 
 
Strategic Priorities Affected 
(3) Engineer sub-regional cluster growth 
(4) Coordinate the provision of specialist business support 
(5) Coordination and development of accommodation and facilities 
(7) Coordinate and create a regional communication and marketing plan  
(8) Promote Exploitation of technology  
(9) Build a high level skills base for region  
(10) Increase access to funding for growth and development 
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6.7 Tactical Intervention G: Improve access to European and National 
funding to support adoption of innovation 
 
Owner – Medilink EM 
 
Description 
Central to the RES and East Midlands Innovation strategies is the need to maximise the 
region’s economic prospects through science, research and innovation. This will involve the 
exploitation of the region’s research base to generate new products and processes, and 
improve competitiveness. Currently, research & development investment in the East Midlands 
is dominated by a few large businesses, with relatively little undertaken by SMEs5. De 
Montfort University have recently started a £2 million pilot project to commercialise new 
products and processes in the East Midlands region, using University expertise to develop 
intellectual property that is latent in both private and public sector organisations. The project 
will capitalise on existing strengths and initiatives in the region to address one of its perceived 
weaknesses - the level of turnover from new products and services, which is reported to be 
lower in the East Midlands than most other regions. The project will establish the scope for 
improving this issue by piloting a proactive and managed innovation process and aims is to 
work with the NHS Hubs. 
 
There are a number of other sources of funding for R&D of which the European Union’s (EU) 
7th Framework Programme (FP7) is the largest ( >€50 billion over 7 years). However, the 
East Midlands has seen a drop of 41% in the participation rate between the last programmes, 
FP5 and FP6. The RES recognises that more must be done to stimulate and facilitate greater 
participation in FP7, particularly by SMEs. 
 
There are a number of factors that have deterred SMEs from taking part in previous 
Framework Programmes: 
 
• The need for coherence between SMEs research goals and what the EU will fund. 
• The high level of responsibility required to work in a consortium (technical, 
administrative and financial). 
• Considerable resource (time and money) commitment in project preparation and 
participation with inherent cash flow issues for SMEs. 
• The length of commitment required (2-5 years). 
• Lack of understanding of the process and bureaucracy involved 
 
In order to overcome these issues, a number of coaching and facilitation activities need to be 
put in place: 
 
• Provide strategic information on calls 
• Identify contacts with the Commission 
• One to one support in preparation of framework proposals 
• Initial assessment and options analysis 
• Focus and direct applications 
• Identifying partners  
• Build consortia and agreements 
• Contract negotiations 
 
Delivery 
The delivery would be managed by Medilink EM utilising successful commercial services 
already available (e.g. Pera and other organisations specialising in EU funding). 
It is anticipated that delivery would be channelled through the iNet. 
 
 
 
                                                     
5 East Midlands Regional Economic Strategy published for review by emda, Regional Economic 
Strategy for the East Midlands “A Flourishing Region”, 12th January 2006 
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Cost & Funding 
 
A three year programme of support to SMEs. Up to 6 support packages of £15,000 for SMEs 
to cover 50% of proposal development, total £90,000. In addition, up to 4 specific SME 
projects will be identified to receive full (£30,000) funding in the first year, total £120,000. A 
manager’s salary and overhead would also need to be paid at £50-£70,000. 
 
It is envisaged that after the first year, 10 support packages of £15,000 would be awarded in 
each of the following two years.  From year 4 onwards, Medilink EM would cover the cost of 
the manager. 
 
Outcomes 
The primary outcome will be to support up to 10 SMEs per annum to increase their R&D 
activity by engagement in FP7 and thereby increase innovation. This links to the following 
RES Strategic Sub Priorities: 
 
2b – Creating a dynamic SME base 
2d – Overcoming barriers to SME growth 
3a – Increasing investment in R&D, and developing research excellence 
3b – helping business deploy technologies and processes 
3d – Commercialising Scientific Excellence 
3e – Growing the Region’s Key Sectors 
 
Strategic Priorities Affected 
(2) Access to the global market 
(3) Engineer sub-regional cluster growth 
(4) Coordinate specialist business support 
(10) Increase access to and take up of funding 
 
 
6.8 Tactical Intervention H:  Lead and coordinate sector specialist 
business support infrastructure 
 
Owner – Medilink EM 
 
Description 
The nature of the Healthcare and Bioscience market, both in the UK and globally, 
necessitates that any specialist business support, over and above the generic support for e.g. 
business planning, financial planning and management that will be provided by the new 
Business Link service operated by East Midlands Business (EMB), requires an understanding 
of the market and its drivers. In addition, SMEs have been confused in the past by the 
plethora of support mechanisms that have been available. Therefore, in order to ensure that 
best value is derived from specialist business support and that access to this support is clear, 
simple and easy to navigate, the support infrastructure must be led and coordinated 
appropriately. Furthermore a fund to cover the time commitment provided by a pool of 
appropriate mentors would help ensure that suitable support is available. It is envisaged that 
specialist business support will be coordinated with EMB and that a referral system will be 
established to appropriately direct companies from the generic support of Business Link to the 
specialist sector support 
  
Delivery 
Medilink EM already coordinates many aspects of specialist business support through its links 
with Healthcare and Bioscience advisors at Business Link, UKTI, BioCity, and the NHS 
Innovation Hub. It is envisaged that this role would continue as an aspect of the Healthcare 
and Bioscience iNet. 
 
Cost and Funding 
A Mentor fund of £25, 000 per annum; 100 days at £250 per day.  
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There would also need to be an initial PR and marketing budget to develop the collateral to 
communicate services to the SME base within the region, and also overhead funding to 
establish links with International quangos, trade associations and support organisations; total 
£50,000. In addition, the salary and overhead of a manager would need to be paid at £60-
£80,000. 
 
Outcomes 
The primary outcome would be a pulling together in a single point of reference all specialist 
Healthcare and Bioscience business support initiatives. It is anticipated that through all iNet 
activities, innovation support would be provided for a total of 40-50 companies per year. 
 
The following RES sub strategies are impacted: 
1a – Developing the skill levels of the workforce 
2a – Building an enterprise culture 
2b – Creating a dynamic SME base 
2d – Overcoming barriers to SME growth 
2h – Supporting SMEs to harness public procurement opportunities 
3a – Increasing investment in R&D 
3b – Helping business deploy technologies and processes 
3c – Resource efficiency through effective use of technology and management pratices 
3d – Commercialising Scientific Excellence 
3e – Growing the Region’s Key Sectors 
 
Strategic Priorities Affected 
(1) Support companies to overcome regulatory barriers 
(2) Facilitate access to global market place 
(3) Engineer sub-regional cluster growth 
(4) Coordination of specialist business support 
(5) Coordination and development of accommodation and facilities 
(6) Support companies to access high level business intelligence 
(7) Coordinate and create a regional communication and marketing plan 
(8) Promote exploitation of technology and know-how 
(9) Build high level skills base 
(10) Increase access to and take up of funding 
 
6.9 Tactical Intervention I: Continuation of the regulatory affairs, 
clinical evaluation and NHS procurement networks 
 
Owner – Medilink EM/ NHS Inn. Hub 
 
Description 
The Healthcare and Bioscience sector is a highly regulated industry, which relies on a 
multitude of guidelines to ensure compliance. The regulations and guidance differ in the 
various global markets because they are governed by different bodies e.g. the Medicine and 
Healthcare products Regulatory Agency (MHRA) in the UK, and the Food and Drug 
Administration (FDA) in the USA. For a new product or service to successfully enter this 
market an understanding of appropriate regulations is essential from inception, through 
clinical evaluation to market. This can be a significant resource burden to SMEs. Within the 
UK, the NHS remains the largest single market (>£76 billion annually) which represents a 
significant opportunity to regional business. However, the benefits of innovations can fail to 
reach this market because companies do not understand the procurement routes or are 
unable to penetrate them.   
 
A network with key regulatory, clinical evaluation and procurement links has been developed. 
However, as a result of the almost continual changes taking place in the NHS and the ever 
changing regulatory landscape, this network requires constant refinement in order to be 
effective. In addition, outlining the framework is not always sufficient for resource limited 
SMEs, who need to be specifically guided through the process. Through the continuation of 
the regulatory affairs, clinical evaluation and NHS procurement networks (which are due to 
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stop in July 2007), SMEs could be guided through the various processes. Specific activities 
would include: 
• Liaison with NHS clinical trials buildings and facilities to ensure complementary 
development with regional needs. There are a number of highly respected clinical 
trails facilities within the NHS in the East Midlands which are currently focused on 
developments at a national and international level.  These facilities are key 
resources in the region and better communication between local companies and 
the NHS strategy boards would deliver significant advantages in delivery of high 
quality clinical trials support and execution. 
• Bridge the existing gap between NHS R&D governance and ethics procedures and 
regional SMEs to accelerate product development. The internal process of R&D 
governance within the NHS is not well understood by external companies and is 
often cited as a reason for them not pursuing potential clinical products.  NHS 
processes are very focused on the internal governance of research often with little 
input from external bodies as to what would be required by them to commission a 
clinical trial.  There is a recent establishment of a Clinical Trials Support Unit 
(CTSU) at University Hospitals of Leicester which, in conjunction with the other 
regional CTSUs could provide the tools to help in planning a clinical trial.  However, 
there is a gap between the skills in local companies that are required to fulfil 
regulatory applications and the provision of central human resources with the 
capacity to fill that gap. Provision of specialists in this area would significantly lower 
the barriers to product development. 
• A Healthcare and Bioscience specific proof of concept fund would enable 
innovative ideas to be developed and then evaluated through the networks. 
• Support in the completion of tenders for NHS contracts.  
 
  
Delivery 
The network would be maintained by Medilink EM who would continue to employ a manager 
to coordinate activities. In addition, 2 FTE joint posts between Medilink EM and the East 
Midlands NHS Innovation Hub would spend time in NHS R&D departments and at specific 
companies to support regulatory applications. 
A fund would be set up to provide £10,000 grant support to SMEs to develop an innovative 
proof of concept product. 
 
Costs and Funding 
Co-ordination between regional NHS R&D Directors and company representatives:  £20,000 
per annum. 
 
2 FTEs salaries and overheads paid at £50-£70,000 each. 
 
Up to ten loans of £10,000 would be made each year for a total of £100,000. 
 
A manager’s salary and overhead would also need to be paid at £60-£80,000. 
 
Outcomes 
The primary outcomes will be: 
(a) Consolidation of the networks in to the regions first point of call for regulatory, 
clinical evaluation or procurement support. 
(b) Up to 5 SMEs supported in regulatory requirements per year 
(c) Up to 5 SMEs completing NHS procurement deals per year 
(d) Up to 10 SMEs completing the approval process for clinical trial applications per 
year 
 
The following RES sub strategies are impacted: 
1a – developing the skill levels of the workforce 
2b – Creating a dynamic SME base 
2d – Overcoming barriers to SME growth 
2h – Supporting SMEs to harness public procurement opportunities 
3a – Developing research excellence 
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3b – Helping business deploy technologies and processes 
3d – Commercialising Scientific Excellence 
3e – Growing the Region’s Key Sectors 
 
Strategic Priorities Affected 
  
(1) Support companies to overcome regulatory barriers 
(2) Facilitate access to the global market place 
(4) Coordination of specialist business support 
(6) Support companies to access high level business intelligence 
(8) Promote exploitation of technology and know-how 
(9) Build high level skills base 
 
 
6.10 Tactical Intervention J: Healthcare and Bioscience specific training 
 
Owner - Medilink 
 
Description 
The Healthcare and Bioscience sector has specific training needs around regulatory and 
clinical evaluation requirements of new product and process development. The success of the 
training provided by Medilink EM as part of the funding received from the dti Harnessing 
Genomics initiative has clearly demonstrated the need for appropriate training specific to the 
sector. Areas of training need include, EU and US legislation, quality systems, and Good 
Clinical Practice (GCP). The latter applies not only to company employees but also to clinical 
staff engaged in commercial clinical trials, where the delivery of a high quality clinical trial is 
critically dependent on there being adequately trained staff.  A regional drive to ensure a 
minimum level of staff trained to GCP standards would make the region significantly more 
attractive to commercial clinical trials. 
In addition, whilst Total Entrepreneurial Activity (TEA) in the East Midlands has increased in 
recent years to now above the UK average6 more still needs to be done if we are to achieve 
the levels of entrepreneurship of the leading regions of the world7.  The low number of 
Healthcare and Bioscience entrepreneurs within the region has been identified as a key 
market failure when compared to successful Healthcare and Bioscience clusters in other 
regions such as Oxford, Cambridge and London. In these other regions success can, in part, 
be attributed to the presence of a core network of serial entrepreneurs who move from 
business to business imparting their knowledge and expertise before moving on to the next 
venture.  An entrepreneur development course will therefore be established in which budding 
Healthcare and Bioscience entrepreneurs will learn from successful Healthcare and 
Bioscience entrepreneurs. This will be done using an action learning model and will need to 
engage internationally renowned Healthcare and Bioscience entrepreneurs. 
 
Delivery 
Medilink EM has delivered 6 regulatory focused workshops over the past year using 
appropriate expertise from its networks. It is proposed that Medilink EM will expand this into a 
monthly programme. Medilink EM would also coordinate the entrepreneur development 
programme in conjunction with an appropriate organisation experienced in this type of 
initiative. 
 
Costs and Funding 
• Workshops: £250 (50%) subsidy to attend, 12 workshops per year with an average 
of 10 delegates per workshop, total cost £45,000. 
• Initial development of the entrepreneur programme £60,000.  
• Subsidy £5, 000 per delegate (50% of costs) with 10 delegates = £50,000.  
                                                     
6 Department for Trade & Industry, 'Regional Competitiveness and State of the Regions', 
May 2005, published in: emda, ‘RES Evidence Base: The East Midlands in 2006- Section 3: Economy and Productivity’, 2006 
7 East Midlands Regional Economic Strategy published for review by emda, Regional Economic Strategy for the East Midlands 
“A Flourishing Region”, 12th January 2006 
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• Management and overheads £50-70,000. 
 
It is envisaged that in year 2, management costs would be £30,000 and delegates would 
receive £2500 (25%) subsidy with 2 courses being run per year, total of 20 delegates. And by 
year 3, the course should have sufficient recognition that people would pay full costs. 
However, a quarter of spaces (5 of 20) would receive a 25% bursary, based on pre-
determined specific selection criteria. 
 
Outcomes 
The primary outcomes would be: 
• 100 employees trained in Healthcare and Bioscience specific topics per year (12 
workshops with average of 10 delegates) 
• 10 Healthcare and Bioscience ‘potential’ serial entrepreneurs completing the 
development programme per year. 
 
The following RES sub strategies are impacted: 
1a – developing the skill levels of the workforce 
1b – Stimulating business demand for skills 
2a – Building an enterprise culture 
2b – Creating a dynamic SME base 
2d – Overcoming barriers to SME growth 
3e – Growing the Region’s Key Sectors 
 
Strategic Priorities Affected 
(1) Support companies to overcome regulatory barriers 
(2) Facilitate access to global market place 
(3) Engineer sub-regional clusters 
(4) Coordination of specialist business support 
(7) Coordinate and create a regional communication and marketing plan 
(8) Promote exploitation of technology and know-how 
(9) Build high level skills base 
(10) Increase access to and take up of funding 
 
 
6.11 Tactical Intervention K: Targeted international trade support 
 
Owner – UKTI  
 
Description 
At a National level UKTI’s 5 year strategy (July 2006) has an emphasis on emerging markets, 
as well as high technology and R&D. 
 
A focus on high technology and R&D companies could prove to be very beneficial to the 
regions Healthcare and Bioscience SMEs, depending on the specific qualifying criteria for the 
support available. However, a marketing focus on emerging markets is likely to be of interest 
to only a small proportion of Healthcare and Bioscience companies. There are, therefore, a 
number of opportunities for tactical interventions that are congruent to the overall UKTI 
strategy and regional funds are available to help companies explore the markets that best suit 
their needs. 
 
These are likely to include: 
• Supporting Healthcare and Bioscience SMEs with trade to key Western markets. 
With the USA constituting the largest world market for medical devices, c. 40%, and 
the European market, at c.32% as the second largest market8, a focus on these is 
strategically important to help the Healthcare and Bioscience sector’s SMEs grow.  
                                                     
8 MEDICAL DEVICES COMPETITIVENESS AND IMPACT ON PUBLIC HEALTH EXPENDITURE, Study prepared for 
the Directorate Enterprise of the European Commission July 2005 
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• Coordinating, managing and promoting Commercial Officer visits to the East 
Midlands. As a free of charge service to SMEs, these have proved to be very 
popular. emda sector funding has already been used to provide marketing support 
and coordination of these visits up to March 2008, and if successful this is expected 
to continue for the remaining two years that UKTI sector projects currently run. As 
well as the continued coordination of these visits, an opportunity exists to combine 
several Commercial Officer visits with Medilink EM’s Innovation Day, which 
attracted 150 attendees this year. Similarly global events such as Medica, that 
attract Commercial Officers from all over the World, could be used for planning 
meetings between these contact and regional SMEs. And by combining with pre-
arranged business meetings, a value added service could be established over and 
above supporting companies to exhibit. 
 
Delivery 
The regional UKTI team would manage these activities, to ensure congruity with national 
UKTI strategy, with support from Medilink,. 
 
Costs and Funding 
To be agreed with regional UKTI team. 
 
Outcomes 
The primary outcome would be 10-20 SMEs supported to visit key global Healthcare and 
Bioscience markets and 20-30 SME meeting with Commercial Officers per year.  
 
The following RES sub strategies are impacted: 
2d – Overcoming barriers to SME growth 
2e – Supporting companies to become internationally competitive 
3e – Growing the Region’s Key Sectors 
 
Strategic Priorities Affected 
(1) Support companies to overcome regulatory barriers 
(2) Facilitate access to global market place 
(3) Engineer sub-regional clusters 
(4) Coordination of specialist business support 
(6) Support companies to access high level business intelligence 
 
 
7 Implementation Timetable 
 
Delivery of this strategy is expected to commence before the end of 2007, once the strategic 
priorities have been agreed by all partners, and is expected to continue over the lifetime of 
this document; subject to periodic reviews and appropriate updating in response to market 
changes. A detailed implementation timetable will be produced once strategic priorities have 
been agreed. Individual tactical interventions are expected to be implemented as outlined in 
Section 5. 
